RANI Rani Therapeutics
- 2.080
- +0.040+1.96%
- 2.100
- +0.020+0.96%
Rani Therapeutics News
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
Rani Therapeutics Advances in Biotherapeutics Market
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)
Rani Therapeutics' Weight-Loss Drugs Can Serve Specific Needs -- Market Talk
Rani Therapeutics | 10-Q: Q3 2024 Earnings Report
Rani Therapeutics | 8-K: Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics: Runway To Fund Operations Into 3Q 2025 >RANI
Express News | Rani Therapeutics Holdings Inc: Qtrly Loss per Share $0.24
Express News | Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Express News | Rani Therapeutics Q3 Operating Income USD -11.799 Million
Press Release: Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics to Participate in Upcoming Investor Conferences
Maxim Group Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $15
Watching Rani Therapeutics; Zacks Small-Cap Research Gives Stock $12 Price Valuation
Oppenheimer Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $17
Analysts Are Bullish on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Rani Therapeutics Holdings (RANI)
Rani Therapeutics Hldgs Analyst Ratings
H.C. Wainwright Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for Rani Therapeutics: Promising Developments in Oral Obesity Treatment With RaniPill
Rani Therapeutics(RANI.US) 10% Shareholder Sells US$10.14 Million in Common Stock
$Rani Therapeutics(RANI.US)$ 10% Shareholder South Cone Investments Limited Partnership sold 3.83 million shares of common stock on Oct 15, 2024 at an average price of $2.6484 for a total value of $10
Analysis
Price Target
No Data
No Data